Oncotarget Study Reveals Effects of E-Cigarettes on Gum Tissue

There’s been a long-standing debate about the health risks associated with the newest fumological fad, the e-cigarette. It mostly began with arguments about whether smoking or e-cigarettes were better for you, or if e-cigarettes, in fact, posed more of a risk than the traditional tobacco cigarette. Thanks to Oncotarget at least one of those questions has the beginning of an answer. A pioneering study into the risks of e-cigarettes has produced vital information regarding the health risks of using e-cigarettes. Oncotarget is also available on Dove Press.

Dr. Ifran Rahman, a professor at the UR School of Medicine and Dentistry, led the study with the intent of determining what kind of effect e-cigarettes have on gum health. The results reveal that ‘vaping’ as it’s known creates an inflammatory reaction in human gum tissue, a reaction that is aggravated when certain forms of juices are used. E-Cigarette fluids are commonly referred to as ‘juices’ by hobbyists, and the ability to mix a seemingly endless variety of flavors are part of its appeal, as well as its perceived lower health risks over tobacco.

The results of the study reveal that while they may be safer than tobacco (the jury is still out on that one) they are not without their own risks. This is just the beginning of a valuable body of knowledge that will help finally reveal the risks associated with using e-cigarettes as a replacement or substitute for tobacco based products, allowing consumers to make informed decisions about their health.

Oncotarget is a medical journal focused on covering and promoting research on all forms of cancer and the possible causes, treatments, and types in the world today. It is a well-respected journal that was established in 2009 and is published by Impact Journals in Albany N.Y. It’s rigorous peer-review process and cooperation with the researchers has led to a publication that has seen rising popularity and a reputation for constructive, timely, multiple peer-reviewed.

Visit: https://www.facebook.com/Oncotarget/